• Third-generation aromatase inhibitors are considered as first-line therapies for the treatment of advanced estrogen receptor (ER) positive, human epidermal growth factor receptor (HER) 2-negative breast cancer.
• A Markov disease-state transition model was designed to compare the cost-effectiveness of the three treatment regimens -anastrozole, letrozole, and combination therapy of letrozole and palbociclib.
• The analysis was carried out from a third-party payer perspective. The disease state transition probabilities were obtained based on published clinical trials.
• Drug acquisition costs were computed based on average whole sale price in the US; health utilities and costs for chemotherapy and palliative care were obtained from literature.
• All costs were converted to 2014 US dollars.
• Future costs and outcomes were discounted at 5%.
• Multiple one-way sensitivity analyses were conducted by varying treatment costs, efficacy of each treatment and discount rate.
• TreeAge Pro 2015 was used for the model.
• Markov Model outline -
CONCLUSION
• The newly-approved combination therapy of Letrozole and Palbociclib was least cost-effective among all drug treatments under consideration.
• The poor cost-effectiveness of the Palbociclib-Letrozole therapy can be attributed to the higher acquisition cost of Palbociclib. 
